查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球液体切片市场：第六版
市场调查报告书
商品编码
1399822

全球液体切片市场：第六版

The Worldwide Market for Liquid Biopsy, 6th Edition
出版日期: | 出版商: Kalorama Information | 英文 220 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

液体活检已成为一种微创诊断工具，透过分析体液中循环的肿瘤衍生物质，为癌症诊断、治疗和监测提供有价值的资讯。虽然组织活检和影像技术仍然是实体瘤诊断的标准，但液体活检代表了一种替代或补充方法，可以解决与传统方法相关的一些限制和风险。

该报告考察了全球液体活检市场，并提供了市场概述、分析物趋势、应用、癌症类型、地区以及进入市场的公司概况。

目录

第一章执行摘要

第二章 液体切片技术

  • 介绍
  • 目前主要的液体切片技术

第 3 章 循环肿瘤 DNA (ctDNA) 液体切片

第 4 章 循环肿瘤细胞 (CTC) 液体切片

第五章细胞外囊泡和其他液体活检

第6章 多样本液体切片试验

第 7 章 仅用于研究目的的液体活检测试

第八章液体活检产业分析

  • 介绍
  • 比赛阶段
  • 竞争因素
  • 重要市场趋势
  • 个性化医疗
  • 延长世界各地的平均寿命
  • 液体切片新产品
  • 提高基因检测的可近性
  • 监管障碍
  • 第三方付款人承保
  • 经证实的临床实用性
  • 某些癌症的发生率
  • 竞争对手退出液体切片市场

第九章液体切片市场

  • 市场概况
  • 市场预测

第 10 章分析物市场

  • 循环肿瘤DNA
  • 循环肿瘤细胞
  • 细胞外囊泡及其他

第十一章 按应用划分的市场

  • 治疗指导和监测
  • 诊断/筛检
  • 疾病预后

第十二章按癌症类型划分的市场

  • 乳腺癌
  • 大肠癌
  • 肺癌
  • 卵巢癌
  • 前列腺癌
  • 其他

第十三章公司简介

  • 市场公司
  • Adaptive Biotechnologies
  • Agena Bioscience, Inc
  • ANGLE, plc
  • Aspira Women's Health
  • Biocartis Group NV
  • Biocept, Inc.
  • Biodesix
  • CellMax Life
  • Circulogene
  • DiaCarta, Inc
  • Epic Sciences
  • Epigenomics AG
  • Exact Sciences
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc.
  • Freenome, Inc
  • GILUPI GmbH
  • GRAIL
  • Guardant Health, Inc
  • Hologic
  • LungLife AI
  • Menarini-Silicon Biosystems, Spa
  • Myriad Genetics, Inc
  • Natera, Inc
  • NeoGenomics Laboratories, Inc
  • Oncocyte Corporation
  • OncoDNA S.A.
  • Personal Genome Diagnostics
  • QIAGEN N.V.
  • Resolution Biosciences
  • Roche Diagnostics
  • Sysmex-Inostics, Inc
  • Tempus
  • VolitionRx
简介目录
Product Code: 23-048

Liquid biopsies have emerged as a minimally invasive diagnostic tool, analyzing tumor-derived materials circulating in biological fluids to offer valuable information for cancer diagnosis, treatment, and monitoring. While tissue biopsies and imaging techniques remain standard in solid tumor diagnosis, liquid biopsies present an alternative or complementary approach, addressing some of the limitations and risks associated with traditional methods.

Key applications of liquid biopsy testing in clinical oncology include:

1. Early Detection and Diagnosis/Screening:

  • Identifying cancer at an early stage.

2. Alternative Testing Method:

  • When tissue biopsy is challenging or impossible.
  • When the primary site of metastatic disease is unknown.

3. Therapy Personalization and Monitoring:

  • Molecular characterization to select optimal therapy.
  • Monitoring treatment efficacy and adjusting therapy in case of resistance.

4. Disease Monitoring:

  • Observing disease progression, tumor evolution, residual disease.
  • Early detection of recurrence.

5. Prognosis of Disease:

  • Assessing the likely course and outcome of the disease.

The liquid biopsy market is experiencing significant changes, and “ The Worldwide Market for Liquid Biopsy, 6th Edition ” from Kalorama Information provides an in-depth assessment of the market opportunity from 2023 to 2028. The brand new market research report covers various aspects, including market segmentation by region, different types of liquid biopsy (CTC-based, ctDNA-based, EV and Exosome-based, Multi-Analyte-based, and Other Analytes), and cancer types.

Key Market Segments:

  • By Region:
    • North America
    • Europe
    • Asia
    • Rest of World
  • By Type of Liquid Biopsy:
    • CTC-based Liquid Biopsy
    • ctDNA-based Liquid Biopsy
    • EV and Exosome-based Liquid Biopsy
    • Multi-Analyte-based Liquid Biopsy
    • Other Analytes Liquid Biopsy
  • By Type of Cancer:
    • Breast
    • Lung
    • Colorectal
    • Ovarian
    • Prostate
    • Pan-Cancer
    • Other Cancers
  • R&D and Selected Tests:
    • Selected ctDNA-based Liquid Biopsy Tests in Development
    • Selected CTC-based Liquid Biopsy Tests in 2023
    • Selected Liquid Biopsy Tests Assessing Multiple Analytes in 2023

The growing acceptance of liquid biopsy, even during the 6th pandemic, underscores its increasing significance in clinical diagnostics. Liquid biopsy's potential in combination with other technologies further contributes to its expanding applications and market growth.

The report also profiles key companies in the liquid biopsy market. These include:

Top of Form

Bottom of Form

  • Adaptive Biotechnologies
  • Agena Bioscience, Inc.
  • Angle, PLC
  • Aspira Women's Health
  • Biocartis Group Nv
  • Biocept, Inc. (closed)
  • Biodesix
  • Cellmax Life
  • Circulogene
  • Diacarta, Inc.
  • Epic Sciences
  • Epigenomics AG (closed)
  • Exact Sciences
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc. (Roche)
  • Freenome, Inc.
  • Gilupi Gmbh
  • Grail (Illumina)
  • Guardant Health, Inc.
  • Hologic
  • Lunglife AI (Formerly Cynvenio Biosystems)
  • Menarini-Silicon Biosystems, SPA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Neogenomics Laboratories, Inc.
  • Oncocyte Corporation
  • Oncodna S.A.
  • Personal Genome Diagnostics
  • Qiagen N.V.
  • Cell-Free DNA Technologies
  • Ctc Technologies
  • Exosome And Mirna Technologies
  • Resolution Biosciences (Agilent)
  • Roche Diagnostics
  • Sysmex-Inostics, Inc.
  • Tempus
  • Volitionrx

Table of Contents

Chapter One: Executive Summary

  • Introduction
  • Liquid Biopsy Technologies
  • Industry Structure
  • Liquid Biopsy Market Revenues and Forecast
    • Figure 1-1: Market for Liquid Biopsy, 2023-2028 ($M)
    • Figure 1-2: Global Liquid Biopsy Market Share, by Geographic Region, 2023 (%)
    • Table 1-1: Global Liquid Biopsy Market by Geographic Region, 2023-2028 ($M)

Chapter Two: Liquid Biopsy Technologies

  • Introduction
    • Table 2-1: Comparison of Tissue and Liquid Biopsy
  • Current Major Liquid Biopsy Technologies
    • Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies

Chapter Three: Circulating Tumor DNA (ctDNA) Liquid Biopsy

  • Introduction
  • Advantages and Limitations of ctDNA in Liquid Biopsy
  • Current ctDNA-based Liquid Biopsy Tests
    • Table 3-1: Selected ctDNA-based Liquid Biopsy Tests, 2023
  • Biocartis
  • Biodesix
  • CellMax Life
  • Circulogene
  • Diacarta
  • Foundation Medicine (Roche)
  • Guardant Health
  • Inivata (Neogenomics)
  • LungLife AI
  • Myriad Genetics
  • NeoGenomics
  • OncoDNA
  • Personal Genomic Diagnostics (LabCorp)
  • QIAGEN
  • Resolution Biosciences (Exact Sciences)
  • Roche Diagnostics
  • Sysmex-Inostics
  • Tempus
  • ctDNA-based Liquid Biopsy Tests in Development
  • Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development, 2023
    • Exact Sciences
  • Freenome
  • GRAIL

Chapter Four: Circulating Tumor Cells (CTCs) Liquid Biopsy

  • Introduction
  • Challenges in the Development of CTC-based Liquid Biopsy Tests
  • CTC-based Liquid Biopsy Tests
    • Table 4-1: Selected CTC-based Liquid Biopsy Tests, 2023
  • Adaptive Biotechnologies
  • ANGLE
  • CellMax Life
  • Epic Sciences
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN
  • Selected CTC-based Liquid Biopsy Tests in Development
    • Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2023
  • Epic Sciences
  • Liquid Biotech USA

Chapter Five: Extracellular Vesicles and Other Liquid Biopsy

  • Introduction
  • Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
    • Table 5-1: Selected Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2023
  • Aspira Women's Health (formerly Vermillion)
  • Biodesix
  • Exosome Diagnostics
  • Hologic
  • MDxHealth
  • Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
    • Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2023
  • Circulogene
  • OncoCyte
  • Resolution Biosciences (Exact Sciences)
  • VolitionRx

Chapter Six: Multi-Analyte Liquid Biopsy Tests

  • Introduction
  • Liquid Biopsy Tests Based on Multiple Analytes
    • Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2023
  • Biodesix
  • Foundation Medicine (Roche)
  • LungLife AI
  • NeoGenomics
  • OncoDNA
  • Multiple Analyte-based Liquid Biopsy Tests in Development
    • Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2023
  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife AI

Chapter Seven: Liquid Biopsy Tests for Research Use Only

  • Introduction
  • Liquid Biopsy Tests for Research Use Only
    • Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2023
  • Agena Bioscience
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • Natera
  • QIAGEN

Chapter Eight: Liquid Biopsy Industry Analysis

  • Introduction
  • Tiers of Competition
    • Table 8-1: Selected Participants in the Liquid Biopsy Market, 2023
  • Competitive Factors
  • Significant Market Trends
    • Table 8-2: Significant Trends in the Liquid Biopsy Market, 2023
  • Personalized Medicine
  • Increasing Global Life Expectancy
  • New Liquid Biopsy Products
  • Increasing Accessibility of Genetic Testing
  • Regulatory Hurdles
  • Third-Party Payor Coverage
  • Demonstrated Clinical Utility
  • Incidence Rates of Specific Cancers
  • Competitors No Longer in the Liquid Biopsy Market
    • Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market

Chapter Nine: Liquid Biopsy Market

  • Market Overview
    • Table 9-1: Global Liquid Biopsy Diagnostics Market Estimate, by Region, 2023-2028 ($M)
    • Figure 1-2: Global Liquid Biopsy Market, by Geographic Region, 2023 ($M)
    • Figure 9-2: Global Liquid Biopsy Diagnostics Market Estimated Share, by Region, 2023 (%)
  • Market Forecast
    • Figure 9-3: Global Liquid Biopsy Market Forecast, by Region (North America, Europe, Asia Pacific, Rest of World), 2023-2028 ($M)

Chapter Ten: Market by Analyte

  • Circulating Tumor DNA
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
    • Table 10-1: Global Liquid Biopsy Market for ctDNA, 2023-2028 ($M)
  • Circulating Tumor Cells
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
    • Table 10-2: Global Liquid Biopsy Market for CTCs, 2023-2028 ($M)
  • Extracellular Vesicles and Other Analytes
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
    • Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles, 2023-2028 ($M)
  • Multiple Analytes
  • Market Overview
  • Revenue Forecast
    • Table 10-4: Global Liquid Biopsy Market for Multiple Analytes, 2023-2028 ($M)

Chapter Eleven: Market by Application

  • Therapy Guidance and Monitoring
  • Market Overview
  • Revenue Forecast
    • Table 11-1: Liquid Therapy for Therapy Guidance, 2023-2028 ($M)
  • Diagnosis/Screening
  • Market Overview
  • Revenue Forecast
    • Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening, 2023-2028 ($M)
  • Disease Prognosis
  • Market Overview
  • Revenue Forecast
    • Table 11-3: Global Liquid Biopsy Market for Disease Prognosis, 2023-2028 ($M)

Chapter Twelve: Market by Cancer Type

  • Breast Cancer
  • Market Overview
  • Revenue Forecast
    • Table 12-1: Global Liquid Biopsy Market for Breast Cancer, 2023-2028 ($M)
  • Colorectal Cancer
  • Market Overview
  • Revenue Forecast
    • Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer, 2023-2028 ($M)
  • Lung Cancer
  • Market Overview
  • Revenue Forecast
    • Table 12-3: Global Liquid Biopsy Market for Lung Cancer, 2023-2028 ($M)
  • Ovarian Cancer
  • Market Overview
  • Revenue Forecast
    • Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer, 2023-2028 ($M)
  • Prostate Cancer
  • Market Overview
  • Revenue Forecast
    • Table 12-5: Global Liquid Biopsy Market for Prostate Cancer, 2023-2028 ($M)
  • Other Cancers
  • Market Overview
  • Revenue Forecast
    • Table 12-6: Global Liquid Biopsy Market for Other Cancers, 2023-2028 ($M)
  • Pan-Cancer Tests
  • Market Overview
  • Revenue Forecast
    • Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing, 2023-2028 ($M)

Chapter Thirteen: Company Profiles

  • Companies in the Market
    • Table 13-1 Companies in the Liquid Biopsy Market
  • Adaptive Biotechnologies
    • Company Overview
  • Agena Bioscience, Inc.
    • Company Overview
  • ANGLE, plc
    • Company Overview
  • Aspira Women's Health
    • Company Overview
  • Biocartis Group NV
    • Company Overview
  • Biocept, Inc. (closed)
    • Company Overview
  • Biodesix
    • Company Overview
  • CellMax Life
    • Company Overview
  • Circulogene
    • Company Overview
  • DiaCarta, Inc.
    • Company Overview
  • Epic Sciences
    • Company Overview
  • Epigenomics AG (closed)
    • Company Overview
  • Exact Sciences
    • Company Overview
  • Exosome Diagnostics, Inc.
    • Company Overview
  • Foundation Medicine, Inc. (Roche)
    • Company Overview
  • Freenome, Inc.
    • Company Overview
  • GILUPI GmbH
    • Company Overview
  • GRAIL (Illumina)
    • Company Overview
  • Guardant Health, Inc.
    • Company Overview
  • Hologic
    • Company Overview
  • LungLife AI (formerly Cynvenio Biosystems)
    • Company Overview
    • Company Overview
  • Menarini-Silicon Biosystems, Spa
    • Company Overview
  • Myriad Genetics, Inc.
    • Company Overview
  • Natera, Inc.
    • Company Overview
  • NeoGenomics Laboratories, Inc.
    • Company Overview
  • Oncocyte Corporation
    • Company Overview
  • OncoDNA S.A.
    • Company Overview
  • Personal Genome Diagnostics
    • Company Overview
  • QIAGEN N.V.
    • Company Overview
  • Cell-free DNA Technologies
  • CTC Technologies
  • Exosome and miRNA Technologies
  • Resolution Biosciences (Agilent)
    • Company Overview
  • Roche Diagnostics
    • Company Overview
  • Sysmex-Inostics, Inc.
    • Company Overview
  • Tempus
    • Company Overview
  • VolitionRx
    • Company Overview